Bausch + Lomb Corporation Stock Price, News & Analysis

Bausch + Lomb (NYSE/TSX: BLCO) has announced the publication of Phase 3 study results for its LUMIFY Preservative Free redness reliever eye drops in Ophthalmology and Therapy. The study, involving 380 participants, demonstrated that the preservative-free formulation is non-inferior to the original LUMIFY in reducing ocular redness.

The clinical trial showed the new formulation delivers results in one minute and lasts up to eight hours. The study met its primary objective, with participants receiving single drops four times daily for four weeks. Both formulations demonstrated comparable safety profiles and low incidence of side effects like rebound redness when used as directed.

Bausch + Lomb (NYSE/TSX: BLCO) has launched "Eyes Tell the Story: The Impact of Dry Eye," a campaign aimed at educating the public about dry eye through personal stories, imagery, and new survey data. The initiative builds upon their 2024 "Know Your Dry Eye" educational campaign.

The company's latest survey revealed significant findings: 78% of sufferers desire more resources and education on dry eye, 62% incorrectly assume dry eye resolves itself after treatment, and 40% waited six months or more before seeking medical help. The campaign features collaboration with photographer Kayte Demont, who captured portraits of dry eye sufferers including interior designer Alvin Wayne and lifestyle blogger Brianne Manz.

According to the company, approximately 150 million U.S. adults experience occasional or frequent dry eye symptoms, with 38 million living with chronic dry eye disease. The campaign emphasizes the importance of early intervention and highlights that relief options range from over-the-counter drops to prescription treatments.

Bausch + Lomb (NYSE/TSX: BLCO), a global eye health company, has scheduled two important investor events. The company will release its second-quarter 2025 financial results on Wednesday, July 30, 2025, at 8:00 a.m. ET, followed by a conference call and live webcast to discuss results and provide a business update.

Additionally, Bausch + Lomb will host an investor day on Thursday, November 13, 2025, where it plans to present a business update and showcase its innovative product pipeline. Further details about the investor day will be provided closer to the event date.

Bausch + Lomb (NYSE/TSX: BLCO) has successfully completed several significant financing transactions. The company closed an upsized offering of €675 million senior secured floating rate notes due 2031 and executed a partial credit agreement refinancing including a $2.325 billion term B loan facility and an $800 million revolving credit facility.

The notes will bear interest at three-month EURIBOR plus 3.875% per year with a 0% floor. The term B loans carry an interest rate of 4.25% for SOFR Loans and 3.25% for ABR Loans. The proceeds were used to refinance existing debt facilities and pay related expenses.

Bausch + Lomb announced the pricing of an upsized €675 million senior secured floating rate notes offering due 2031, increased from the initially planned €600 million. The Notes will be sold at 99.500% of principal value. The company is also seeking to obtain a $2.325 billion new term B loan facility (increased from $2.2 billion) with Term SOFR + 4.25% interest rate, and an $800 million revolving credit facility. The proceeds will be used to repay existing revolving credit facility borrowings, refinance term A and B loans due 2027, and cover related expenses. The Notes will be guaranteed by the company and its subsidiary guarantors, secured by first priority liens. Both the Notes offering and new credit facilities are expected to close on June 26, 2025.

Bausch + Lomb (NYSE/TSX: BLCO) has announced a significant refinancing initiative involving multiple components. The company's subsidiaries are launching a €600 million senior secured floating rate notes offering. Additionally, BLCO is seeking to establish a new $2.2 billion term B loan facility and an $800 million revolving credit facility. The proceeds will be used to refinance existing debt, including repaying outstanding revolving credit facility borrowings and refinancing term A and B loans due 2027. The notes will be guaranteed by the company and its subsidiary guarantors, secured by first-priority liens on assets that secure the company's credit agreement obligations. The offering is limited to qualified institutional buyers in the US under Rule 144A and non-US persons under Regulation S, with Canadian sales restricted to exempt transactions.

Bausch + Lomb (NYSE/TSX: BLCO) has launched two new preservative-free lubricating eye drops in the United States: Blink Nourish and Blink Boost. Blink Nourish, priced at $15.99 for 10mL, is the first vitamin-enriched preservative-free eye drop containing vitamin B12, vitamin C, magnesium, and amino acids, designed to replenish the tear film. The formula includes hyaluronan and trehalose for tear film stability. Blink Boost, priced at $13.99 for 10mL, features a pH-balanced formula matching healthy tears and contains hyaluronan, electrolytes, and antioxidants. Both products are contact-lens friendly and available at major U.S. retailers including Walmart, Target, CVS, Walgreens, and Amazon.

Bausch + Lomb (NYSE/TSX: BLCO) announced that CFO Sam Eldessouky will participate in the 2025 Jefferies Global Healthcare Conference. The presentation is scheduled for June 4, 2025, at 7:35 a.m. ET in New York City. Investors can access a live webcast of the conference through the company's Investor Relations website. Bausch + Lomb is a global eye health company focused on helping people improve their vision and quality of life.

Bausch + Lomb (NYSE/TSX: BLCO) held its 2025 Annual Meeting of Shareholders on May 21, 2025, where shareholders elected all 10 nominated directors to the board. The meeting resulted in strong approval rates for all nominees, with each director receiving over 337 million votes in favor.

Additionally, shareholders approved several other key measures including: a non-binding advisory vote on executive compensation, the appointment of PricewaterhouseCoopers LLP as the company's auditor until the 2026 Annual Meeting, and authorization for the board to determine the auditor's remuneration.